Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 27;8(16):4410-4413.
doi: 10.1182/bloodadvances.2024013182.

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Adriano Venditti  1   2 , Alfonso Piciocchi  3 , Anna Candoni  4   5 , Valentina Arena  3 , Raffaele Palmieri  1 , Carla Filì  4 , Angelo Michele Carella  6 , Valeria Calafiore  7 , Roberto Cairoli  8 , Paolo de Fabritiis  9 , Gabriella Storti  10 , Prassede Salutari  11 , Francesco Lanza  12 , Giovanni Martinelli  13 , Antonio Curti  14 , Mario Luppi  5 , Claudia Ingrosso  15 , Maria Paola Martelli  16 , Antonio Cuneo  17 , Francesco Albano  18 , Antonino Mulè  19 , Agostino Tafuri  20 , Laura Cudillo  21 , Alessia Tieghi  22 , Nicola Stefano Fracchiolla  23 , Debora Capelli  24 , Silvia Maria Trisolini  25 , Caterina Alati  26 , Edoardo La Sala  3 , Luca Maurillo  2 , Maria Ilaria Del Principe  1   2 , Maria Antonietta Irno Consalvo  1 , Maria Domenica Divona  2 , Tiziana Ottone  1 , Raffaella Cerretti  2 , Giuseppe Sconocchia  27 , Maria Teresa Voso  1   2 , Paola Fazi  3 , Marco Vignetti  3 , Francesco Buccisano  1   2
Affiliations

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Adriano Venditti et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.V. reports consultancy fee from Novartis, Pfizer, Jazz Pharmaceuticals, Amgen, AbbVie, Gilead, Astellas, Incyte, Medac, AstraZeneca, Servier, Daiichi Sankyo, Janssen-Cilag, Menarini-StemLine, and Laboratories Delbert; research funding from Sandoz and Jazz Pharmaceuticals; speaker bureau fees from Pfizer; and invited speaker fees from Bristol Myers Squibb, Pfizer, AbbVie, Novartis, AstraZeneca, Janssen-Cilag, Astellas, and Daiichi Sankyo. A. Candoni reports consultancy fees from Pfizer, Jazz Pharmaceuticals, Amgen, AbbVie, Gilead, Astellas, Incyte, Servier, Janssen-Cilag, and Laboratories Delbert; and invited speaker fees from Bristol Myers Squibb, Pfizer, AbbVie, Incyte, Janssen-Cilag, and Astellas. R.C. reports consultancy fees from Novartis, Pfizer, Jazz Pharmaceuticals, AbbVie, Gilead, Astellas, Servier, Janssen-Cilag, and BeiGene; and research funding from Novartis. F.L. reports research grant from Pfizer; and advisory board fees from Jazz. G.M. reports consultant/advisor/speaker bureau fees from Ariad/Incyte, Pfizer, Celgene/Bristol Myers Squibb, Amgen, Roche, AbbVie, GlaxoSmithKline, Astellas, Daiichi Sankyo, Takeda, and Janssen; and research support from Pfizer, AbbVie, AstraZeneca, Daiichi Sankyo, Takeda, and Ariad/Incyte. A. Curti reports advisory board fees and meeting with honoraria from AbbVie, Pfizer, Novartis, and Jazz Pharma. M.L. reports advisory board fees from AbbVie, Gilead sci, Jazz Pharma, Novartis, Merck Sharp & Dohme, Grifols, Sanofi, and Daiichi Sankyo. M.P.M. reports honoraria from Rasna Therapeutics, Inc for scientific adviser activities and honoraria/consultancy at scientific advisory board for AbbVie, Amgen, Celgene, Janssen, Novartis, Pfizer, and Jazz Pharmaceuticals. D.C. reports research funding from Seattle Genetics, Pfizer, Daiichi Sankyo, and AstraZeneca. F.B. reports consultancy fees from Jazz Pharmaceuticals, Novartis, and Laboratories Delbert; and research funding from Becton Dickinson; invited speaker fees from AbbVie, Jazz Pharmaceuticals, Bristol Myers Squibb, Janssen-Cilag, and Astellas. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
OS and DFS of the study population and of IR patients. (A-B) Six-year OS (A) and DFS (B) by risk category. (C-D) 6-year OS (C) and DFS (D) in IR patients MRD-negative (<0.035%) for the blue curve and MRD-positive (>0.035%) for the yellow one.
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. - PubMed
    1. Michaelis LC. Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. Hematology Am Soc Hematol Educ Program. 2018;2018(1):51–62. - PMC - PubMed
    1. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753–2767. - PMC - PubMed
    1. Acute Myeloid Leukemia. Version 1.2009 NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
    1. Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935–945. - PubMed

Publication types